- FoI Number
- 2024-560
- Subject
- Asthma Treatment
- Date Received
- 12/12/2024
- Request and Response
-
Q1. How many patients have been treated (for any condition) in the last 4 months with:
Benralizumab
<5
Dupilumab
8
Omalizumab
<5
Reslizumab
0
Mepolizumab
<5
Tezepelumab
<5
Where we have given < 5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38 (1) (b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
Age 6 - 11
0
Age 12 - 17
<5
Age 18 and above
16
Where we have given < 5 answers, this is because NHS Shetland considers that providing more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38 (1) (b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
Q3. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with:
• Benralizumab
• Dupilumab
• Omalizumab
• Reslizumab
• Mepolizumab
• Tezepelumab
In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. At present, NHS Shetland does not have indication based prescribing.
